당뇨병성 족부궤양 생물제제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Diabetic Foot Ulcer Biologics Market Size, Share & Trends Analysis Report By Product, By Indication, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

당뇨병성 족부궤양 생물제제 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 당뇨병성 족부궤양 생물제제 시장 규모는 2030년까지 31억 1,000만 달러에 달할 것으로 예측되고, 2025-2030년의 CAGR은 7.9%를 나타낼 것으로 예상됩니다.

이 성장의 배경에는 시장 진출기업 간의 경쟁 격화, 연구 활동의 활성화, 고령자 증가에 수반하는 임상 검사 및 연구 증가가 있습니다.

예를 들어, 2022년 8월에 국립의료도서관에서 발표된 연구에서는 DFU의 위험이 연령에 따라 증가하는 것으로 보고되었습니다. 따라서, 고령자 증가는 당뇨병성 족부궤양 증가로 이어질 것으로 예상됩니다.

• 2030년까지 세계의 6명 중 1명이 60세 이상이 되어, 이 연령층의 인구는 2020년의 10억명으로부터 14억명으로 증가할 것으로 예상됩니다.
• 2050년에는 세계의 60세 이상의 인구는 두배로 21억명에 이를 것으로 추정되고 있습니다.
• 80세 이상의 인구는 2020-2050년에 걸쳐 3배로 증가해, 4억 2,600만명에 이를 것으로 예측되고 있습니다.

또한, 당뇨병성 족부궤양의 혁신적인 치료법을 개발하기 위해 여러 기업이 진입하고 있으며, 임상검사의 수가 증가하고 있는 것도 예측기간 중 시장의 견인역이 될 것으로 예상됩니다. 다양한 산업 참가자들이 신규 생물 제제를 제공하기 위해 임상 검사에 적극적으로 노력하고 있습니다. 예를 들어, 2025년 1월, 임상 단계의 재생 의료 기업인 RION은 당뇨병성 족부궤양(DFU) 치료에서 정제된 엑소좀 제형(PEP)의 2상 임상 검사에 대한 환자 등록 완료를 발표했습니다. 이 긍정적인 다기관 공동 비 맹검 검사는 미국 내 59 명의 환자를 등록하고 표준 상처 치료와 병행하여 PEP를 국부적으로 적용한 경우의 안전성과 효능을 평가하는 것을 목표로합니다. PEP는 인간 혈소판 유래의 독특한 동결건조 분말로 안정화된 재생 엑소좀을 함유하고 있습니다. 이 엑소좀은 상처 치유를 성공시키는데 필수적인 요소인 상처 받기 쉬운 조직을 보호하는 동시에 세포 증식을 촉진하고 염증을 억제함으로써 신체의 자연 치유 과정을 향상시키기 위해 설계되었습니다.

당뇨병성 족부궤양 생물제제 시장 보고서 하이라이트

• 제품별로, 2024년 당뇨병성 족부궤양 생물제제 시장은 피부 대체물 부문이 세계 시장을 독점했습니다. 한편, 조직 공학 제품 부문은 향후 몇 년동안 가장 빠르게 성장할 것으로 예상됩니다.
• 적응증별로, 신경 허혈성 궤양 부문은 2024년 시장에서 약 53.17%의 최대 수익 점유율을 차지했습니다. 대조적으로, 허혈성 당뇨병성 발 궤양 부문은 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 최종 용도별로 병원 부문은 시장을 독점했으며 2024년에는 51.52%의 수익 점유율을 차지했습니다. 반면 외래수술센터(ASC) 부문은 예측 기간 동안 가장 빠른 성장이 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 당뇨병성 족부궤양 생물제제 시장 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회 분석
  • 시장 과제 분석
• 당뇨병성 족부궤양 생물제제 시장 분석 도구
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 당뇨병성 족부궤양 생물제제 시장 : 제품 추정·동향 분석

• 부문 대시보드
• 세계의 당뇨병성 족부궤양 생물제제 시장 변동 분석
• 세계의 당뇨병성 족부궤양 생물제제 시장 규모와 동향 분석(제품별, 2018-2030년)
  • 피부 대체물
  • 성장 인자
  • 조직 공학 제품

제5장 당뇨병성 족부궤양 생물제제 시장 : 적응증 추정·동향 분석

• 부문 대시보드
• 세계의 당뇨병성 족부궤양 생물제제 시장 변동 분석
• 세계의 당뇨병성 족부궤양 생물제제 시장 규모와 동향 분석(적응증별, 2018-2030년)
  • 신경 허혈성 궤양
  • 신경병증 당뇨병성 족부궤양
  • 허혈성 당뇨병성 족부궤양

제6장 당뇨병성 족부궤양 생물제제 시장 : 최종 용도 추정·동향 분석

• 부문 대시보드
• 세계의 당뇨병성 족부궤양 생물제제 시장 변동 분석
• 세계의 당뇨병성 족부궤양 생물제제 시장 규모와 동향 분석(최종 용도별, 2018-2030년)
• 병원
• 클리닉
• 외래수술센터(ASC)
• 장기 요양 시설
• 기타

제7장 당뇨병성 족부궤양 생물제제 시장 : 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측, 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 인도
  • 중국
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 공급업체 상황
  • 주요 리셀러와 채널 파트너 목록
  • 주요 기업의 시장 점유율 분석(2024년)
  • Organogenesis Holdings Inc.
  • Tissue Regenix
  • BioTissue
  • Integra LifeSciences
  • MIMEDX Group, Inc.
  • Convatec Inc.
  • Coloplast Group(Kerecis)
  • Biocomposites
  • Smith Nephew, Inc.
  • Stedical Scientific, Inc.
  • Zimmer Biomet
  • GUNZE LIMITED
• 히트맵 분석/기업시장 포지셔닝 분석
• 2024년 기업의 시장 점유율 예측 분석
• 기타 주요 시장 진출기업 일람

KTH

영문 목차

영문목차

Diabetic Foot Ulcer Biologics Market Growth & Trends:

The global diabetic foot ulcer biologics market size is anticipated to reach USD 3.11 billion by 2030 and is projected to grow at a CAGR of 7.9% from 2025 to 2030, based on a new report by Grand View Research, Inc. This growth can be attributed to the growing competition among the market participants, rising research activities, the increasing number of clinical trials and studies along with increasing geriatric population. Moreover, the rising focus of industry players on expanding their presence is anticipated to propel market growth in the coming years.

For instance, a study from the National Library of Medicine in August 2022 reported that the risk of DFU increases with age. This correlation is closely linked to the longer duration of diabetes, the cumulative effects of hyperglycemia, and a higher prevalence of micro- and macrovascular complications. Therefore, the increasing prevalence of the geriatric population is expected to lead to a rise in diabetic foot ulcers. According to data published by the WHO in October 2024, the number of older people is estimated to increase significantly in the coming years. Below are some projections given by the WHO:

• By 2030, 1 in 6 people worldwide will be aged 60 or older, with the population in this age group growing from 1 billion in 2020 to 1.4 billion.
• By 2050, the worldwide population of individuals aged 60 and above is estimated to double, reaching 2.1 billion.
• The number of people aged 80 or older is expected to triple from 2020 to 2050, reaching 426 million.

The increasing number of clinical trials is also expected to drive the market during the forecast period, attracting several companies to develop innovative treatments for diabetic foot ulcers. Various industry participants are actively engaged in clinical studies to bring novel biologics in the industry. For instance, in January 2025, RION, a clinical-stage regenerative medicine company, announced the completion of patient enrollment for its Phase 2 clinical trial of the Purified Exosome Product (PEP) in treating diabetic foot ulcers (DFUs). This prospective, multicenter, open-label study enrolled 59 patients across the U.S. It aims to assess the safety and efficacy of PEP when applied topically alongside standard wound care. PEP is a proprietary, lyophilized powder derived from human platelets that contains stabilized regenerative exosomes. These exosomes are engineered to enhance the body's natural healing processes by promoting cellular growth and reducing inflammation while also protecting vulnerable tissues-crucial elements for successful wound healing.

Diabetic Foot Ulcer Biologics Market Report Highlights:

• Based on product, the skin substitutes segment dominated the global diabetic foot ulcer biologics market in 2024. On the other hand, the tissue-engineered products segment is anticipated to grow at the fastest in the coming years.
• Based on indication, the neuro-ischemic ulcers segment held the largest revenue share of around 53.17% in the market in 2024. In contrast, the ischemic diabetic foot ulcer segment is expected to grow the fastest CAGR over the forecast period.
• Based on end use, the hospital segment dominated the market and accounted for a revenue share of 51.52% in 2024. On the other hand, ambulatory surgical centers segment is expected to grow the fastest over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Third Party Perspective
  • 1.3.5. Primary research
  • 1.3.6. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Data Sources
• 1.8. List of Primary Sources
• 1.9. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Diabetic Foot Ulcer Biologics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of diabetic foot ulcer
    • 3.2.1.2. Technological advancements in biologics
    • 3.2.1.3. Rising geriatric population
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of biologics products
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Rising distribution agreement for biologics
    • 3.2.3.2. Growing number of clinical trials
    • 3.2.3.3. Expansion of manufacturing and distribution facilities
    • 3.2.3.4. Expansion in emerging markets
  • 3.2.4. Market challenge analysis
    • 3.2.4.1. Intense Competition
• 3.3. Diabetic Foot Ulcer Biologics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. Diabetic Foot Ulcer Biologics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
• 4.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.3.1. Skin Substitutes
    • 4.3.1.1. Skin-Substitutes market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.1.2. Biological
      • 4.3.1.2.1. Biological market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.1.3. Synthetic
      • 4.3.1.3.1. Synthetic market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.1.4. Bio-Synthetic
      • 4.3.1.4.1. Bio-Synthetic market estimates and forecast 2018 to 2030 (USD Million)
  • 4.3.2. Growth Factors
    • 4.3.2.1. Growth factors market estimates and forecast 2018 to 2030 (USD Million)
  • 4.3.3. Tissue-Engineered Products
    • 4.3.3.1. Tissue-engineered products market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Diabetic Foot Ulcer Biologics Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
• 5.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.3.1. Neuro-ischemic Ulcers
    • 5.3.1.1. Neuro-ischemic ulcers market estimates and forecast 2018 to 2030 (USD Million)
  • 5.3.2. Neuropathic Diabetic Foot Ulcer
    • 5.3.2.1. Neuropathic diabetic foot ulcer market estimates and forecast 2018 to 2030 (USD Million)
  • 5.3.3. Ischemic Diabetic Foot Ulcer
    • 5.3.3.1. Ischemic diabetic foot ulcer market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Diabetic Foot Ulcer Biologics Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
• 6.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
• 6.5. Clinics
  • 6.5.1. Clinics market estimates and forecast 2018 to 2030 (USD Million)
• 6.6. Ambulatory Surgical Centers (ASCs)
  • 6.6.1. Ambulatory Surgical Centers (ASCs) market estimates and forecast 2018 to 2030 (USD Million)
• 6.7. Long-Term Care Settings
  • 6.7.1. Long-term care settings market estimates and forecast 2018 to 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Diabetic Foot Ulcer Biologics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. market estimates and forecasts, 2018 - 2030
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada market estimates and forecasts, 2018 - 2030
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Reimbursement scenario
    • 7.3.4.5. Mexico market estimates and forecasts, 2018 - 2030
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Competitive scenario
    • 7.4.1.3. Regulatory framework
    • 7.4.1.4. Reimbursement scenario
    • 7.4.1.5. UK market estimates and forecasts, 2018 - 2030
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. Germany market estimates and forecasts, 2018 - 2030
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. France market estimates and forecasts, 2018 - 2030
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. Italy market estimates and forecasts, 2018 - 2030
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Spain market estimates and forecasts, 2018 - 2030
  • 7.4.6. Denmark
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Denmark market estimates and forecasts, 2018 - 2030
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden market estimates and forecasts, 2018 - 2030
  • 7.4.8. Norway
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Norway market estimates and forecasts, 2018 - 2030
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. Reimbursement scenario
    • 7.5.1.5. Japan market estimates and forecasts, 2018 - 2030
  • 7.5.2. India
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. India market estimates and forecasts, 2018 - 2030
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. China market estimates and forecasts, 2018 - 2030
  • 7.5.4. South Korea
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. South Korea market estimates and forecasts, 2018 - 2030
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. Australia market estimates and forecasts, 2018 - 2030
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Thailand market estimates and forecasts, 2018 - 2030
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Reimbursement scenario
    • 7.6.1.5. Brazil market estimates and forecasts, 2018 - 2030
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Argentina market estimates and forecasts, 2018 - 2030
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement scenario
    • 7.7.1.5. South Africa market estimates and forecasts, 2018 - 2030
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. UAE market estimates and forecasts, 2018 - 2030
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Kuwait market estimates and forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Organogenesis Holdings Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Tissue Regenix
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. BioTissue
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Integra LifeSciences
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. MIMEDX Group, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Convatec Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Coloplast Group (Kerecis)
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Biocomposites
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Smith+Nephew, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Stedical Scientific, Inc.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Zimmer Biomet
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. GUNZE LIMITED
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives
• 8.4. Heat Map Analysis/ Company Market Position Analysis
• 8.5. Estimated Company Market Share Analysis, 2024
• 8.6. List of Other Key Market Players

관련자료